MART-1(97-116)

MART-1(97-116) is a synthetic peptide fragment derived from the melanoma antigen recognized by T cells 1 (MART-1), also known as Melan-A. As a well-characterized epitope, this peptide represents amino acids 97 to 116 of the MART-1 protein and is widely utilized in immunological and cancer research. Its sequence is recognized by cytotoxic T lymphocytes (CTLs) in the context of major histocompatibility complex (MHC) molecules, making it a valuable tool for studies focused on antigen-specific immune responses. The defined structure and immunogenic properties of MART-1(97-116) position it as a key reagent for investigating mechanisms underlying tumor immunology, T cell activation, and antigen presentation.

Antigen presentation research: In the context of antigen processing and presentation studies, MART-1(97-116) serves as a model peptide for exploring MHC class I-restricted presentation pathways. Researchers employ this fragment to load antigen-presenting cells (APCs) in vitro, enabling precise investigation into how peptide-MHC complexes are formed, trafficked, and recognized by T cells. Such studies are fundamental to understanding cellular immune surveillance and the molecular events that drive recognition of tumor-associated antigens.

T cell activation assays: The peptide is extensively used in functional assays designed to evaluate the activation, proliferation, and cytotoxicity of MART-1-specific T cells. By pulsing target cells or APCs with this epitope, investigators can monitor T cell responses through cytokine release, proliferation assays, or cytotoxicity measurements. These applications are crucial for dissecting the specificity and potency of T cell responses against melanoma antigens, as well as for validating immune monitoring protocols in preclinical research.

Vaccine development research: MART-1(97-116) is also employed in the development and evaluation of peptide-based vaccine candidates targeting melanoma. Its well-defined immunogenicity allows for the assessment of peptide formulations, adjuvant combinations, and delivery systems aimed at eliciting robust antigen-specific T cell responses. Experimental vaccine studies often utilize this peptide to measure the induction of MART-1-specific immunity in vitro or in animal models, providing insights into the optimization of cancer immunotherapy strategies.

Immunological monitoring: In translational and preclinical studies, the peptide is utilized for immune monitoring applications, such as the detection and quantification of MART-1-specific T cells in peripheral blood samples. Techniques including ELISPOT, flow cytometry with tetramer staining, and intracellular cytokine staining rely on MART-1(97-116) to identify and characterize antigen-specific T cell populations. This enables researchers to track immune responses in various experimental settings and to correlate T cell dynamics with disease progression or therapeutic interventions.

Epitope mapping and specificity studies: The defined sequence of MART-1(97-116) makes it an indispensable reagent for mapping T cell epitopes and studying the specificity of T cell receptor (TCR) recognition. Researchers use this peptide to delineate the minimal epitope required for T cell activation, to analyze cross-reactivity with related peptides, and to investigate the structural determinants of TCR-peptide-MHC interactions. Such studies provide valuable information for designing targeted immunotherapies and for understanding the molecular basis of antigen recognition in tumor immunity.

1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

2. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

5. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes